These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

574 related items for PubMed ID: 19190133

  • 1. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM.
    Clin Cancer Res; 2009 Mar 01; 15(5):1585-92. PubMed ID: 19190133
    [Abstract] [Full Text] [Related]

  • 2. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, Kabbinavar F, Head C, Wong SG.
    PLoS One; 2013 Mar 01; 8(2):e56112. PubMed ID: 23405260
    [Abstract] [Full Text] [Related]

  • 3. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL.
    Cancer Biol Ther; 2011 Sep 01; 12(5):436-46. PubMed ID: 21725209
    [Abstract] [Full Text] [Related]

  • 4. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR.
    Cancer Biol Ther; 2012 Aug 01; 13(10):935-45. PubMed ID: 22785204
    [Abstract] [Full Text] [Related]

  • 5. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
    Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR.
    Clin Cancer Res; 2010 May 01; 16(9):2571-9. PubMed ID: 20388852
    [Abstract] [Full Text] [Related]

  • 6. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
    Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR.
    Clin Cancer Res; 2012 Sep 15; 18(18):4986-96. PubMed ID: 22825581
    [Abstract] [Full Text] [Related]

  • 7. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 8. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
    Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.
    Clin Cancer Res; 2008 Oct 15; 14(20):6456-68. PubMed ID: 18927285
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G.
    Clin Cancer Res; 2004 Jan 15; 10(2):784-93. PubMed ID: 14760102
    [Abstract] [Full Text] [Related]

  • 10. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV.
    Clin Cancer Res; 2009 May 15; 15(10):3484-94. PubMed ID: 19447865
    [Abstract] [Full Text] [Related]

  • 11. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
    Young NR, Liu J, Pierce C, Wei TF, Grushko T, Olopade OI, Liu W, Shen C, Seiwert TY, Cohen EE.
    Mol Oncol; 2013 Jun 15; 7(3):359-68. PubMed ID: 23200321
    [Abstract] [Full Text] [Related]

  • 12. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.
    Clin Cancer Res; 2006 Jul 01; 12(13):4103-11. PubMed ID: 16818711
    [Abstract] [Full Text] [Related]

  • 13. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C, Lu W, Ren Z, Tang Y, Zhang C, Yang R, Chen Y, Cao W, Wang L, Wang X, Ji T.
    Cancer Lett; 2016 Jul 10; 377(1):1-10. PubMed ID: 27090738
    [Abstract] [Full Text] [Related]

  • 14. A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment.
    La Fleur L, Johansson AC, Roberg K.
    PLoS One; 2012 Jul 10; 7(9):e44071. PubMed ID: 23049743
    [Abstract] [Full Text] [Related]

  • 15. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
    Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM.
    Cancer Res; 2013 Jan 15; 73(2):824-33. PubMed ID: 23172311
    [Abstract] [Full Text] [Related]

  • 16. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
    Koch AT, Love-Homan L, Espinosa-Cotton M, Stanam A, Simons AL.
    Cancer Res; 2015 Apr 15; 75(8):1657-67. PubMed ID: 25712126
    [Abstract] [Full Text] [Related]

  • 17. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H, Li X, Lu Y, Qiu S, Fan Z.
    Cancer Lett; 2016 Oct 10; 381(1):23-30. PubMed ID: 27450723
    [Abstract] [Full Text] [Related]

  • 18. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 19. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
    Jameson MJ, Beckler AD, Taniguchi LE, Allak A, Vanwagner LB, Lee NG, Thomsen WC, Hubbard MA, Thomas CY.
    Mol Cancer Ther; 2011 Nov 01; 10(11):2124-34. PubMed ID: 21878657
    [Abstract] [Full Text] [Related]

  • 20. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
    Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, Vogler BW, Thorburn J, Fernandez P, Glogowska MJ, Takimoto SM, Sehrt DB, Gan GN, Eagles-Soukup JR, Serracino H, Hirsch FR, Lucia MS, Thorburn A, Song JI, Wang XJ, Jimeno A.
    Cancer Res; 2013 Jun 01; 73(11):3381-92. PubMed ID: 23576557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.